Literature DB >> 14532843

Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines.

Fanghong Chen1, Peter Langenstroer, Guangjian Zhang, Yoshiki Iwamoto, William A See.   

Abstract

PURPOSE: Autocrine expression of interleukin (IL)-6 by transitional cell carcinoma (TCC) in response to bacillus Calmette-Guerin (BCG) may have an important role in promoting BCG adherence to TCC and consequently in BCG treatment efficacy. IL-6 expression in response to BCG requires nuclear factor (NF)-kappaB mediated signal transduction. We evaluated the influence of androgens on BCG induced, NF-kappaB mediated IL-6 expression.
MATERIALS AND METHODS: Reverse transcriptase-polymerase chain reaction was used to confirm androgen receptor expression in the human TCC lines 253J and T24. A reporter construct containing an androgen response element was used to establish the integrity of androgen mediated signal transduction. Subsequently the dose dependent effect of dihydrotestosterone (DHT) on BCG induced IL-6 expression and NF-kappaB signaling was evaluated. Two pharmacological androgen receptor blockers were used to determine if receptor blockade inhibited the effect of DHT on activation of the androgen response element, NF-kappaB signaling and BCG induced IL-6 expression.
RESULTS: The 2 human TCC lines expressed androgen receptor and demonstrated intact androgen stimulated signaling pathways. DHT suppressed BCG induced, NF-kappaB mediated signaling and IL-6 expression in a dose dependent manner. DHT decreased mRNA levels of IL-6, expression of the full-length IL-6 promoter construct and expression of an NF-kappaB specific reporter construct in response to BCG relative to controls. Competitive pharmacological blockade of androgen receptor inhibited the effect of DHT on BCG induced signaling in dose dependent fashion.
CONCLUSIONS: DHT down-regulates NF-kappaB mediated IL-6 expression by human TCC lines in response to BCG. This effect depends on a functional androgen receptor signaling pathway and it can be blocked by the inhibition of androgen/androgen receptor binding.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14532843     DOI: 10.1097/01.ju.0000092238.15685.10

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Effect of short-term androgen deficiency on bladder contractility and urothelial mediator release.

Authors:  Giselle Bravo; Helen Massa; Roselyn Rose'Meyer; Russ Chess-Williams; Catherine McDermott; Donna J Sellers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-11       Impact factor: 3.000

Review 2.  Impact of gender on bladder cancer incidence, staging, and prognosis.

Authors:  Harun Fajkovic; Joshua A Halpern; Eugene K Cha; Atessa Bahadori; Thomas F Chromecki; Pierre I Karakiewicz; Eckart Breinl; Axel S Merseburger; Shahrokh F Shariat
Journal:  World J Urol       Date:  2011-06-09       Impact factor: 4.226

Review 3.  Role of androgen receptor expression in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.

Authors:  Francesca Sanguedolce; Luigi Cormio; Giuseppe Carrieri; Beppe Calò; Davide Russo; Andrea Menin; Antonio Luigi Pastore; Francesco Greco; Giorgio Bozzini; Antonio Galfano; Giovannalberto Pini; Angelo Porreca; Filippo Mugavero; Mario Falsaperla; Carlo Ceruti; Luca Cindolo; Alessandro Antonelli; Andrea Minervini
Journal:  Histol Histopathol       Date:  2019-12-05       Impact factor: 2.303

4.  The effects of early versus delayed castration targeting androgen on prolonging survival in a mouse model of bladder cancer.

Authors:  Zaixian Zhang; Qingquan Xu; Xiaobo Huang; Jia Yang; Yanhong Xu; Guixiang Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  Role of nicotinic and estrogen signaling during experimental acute and chronic bladder inflammation.

Authors:  Magaly Martinez-Ferrer; Juan M Iturregui; Consolate Uwamariya; Jonathan Starkman; Ali-Reza Sharif-Afshar; Kichiya Suzuki; Wit Visedsindh; Robert J Matusik; Roger R Dmochowski; Neil A Bhowmick
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

6.  Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.

Authors:  Stephen A Boorjian; Hannelore V Heemers; Igor Frank; Sara A Farmer; Lucy J Schmidt; Thomas J Sebo; Donald J Tindall
Journal:  Endocr Relat Cancer       Date:  2008-10-09       Impact factor: 5.678

7.  Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.

Authors:  Zhiqun Shang; Yanjun Li; Minghao Zhang; Jing Tian; Ruifa Han; Chih-Rong Shyr; Edward Messing; Shuyuan Yeh; Yuanjie Niu; Chawnshang Chang
Journal:  Mol Cancer Ther       Date:  2015-08-11       Impact factor: 6.261

Review 8.  The effect of age and gender on bladder cancer: a critical review of the literature.

Authors:  Shahrokh F Shariat; John P Sfakianos; Michael J Droller; Pierre I Karakiewicz; Siegfried Meryn; Bernard H Bochner
Journal:  BJU Int       Date:  2009-11-13       Impact factor: 5.588

Review 9.  Sex Hormone Receptor Signaling in Bladder Cancer: A Potential Target for Enhancing the Efficacy of Conventional Non-Surgical Therapy.

Authors:  Hiroki Ide; Hiroshi Miyamoto
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

Review 10.  Involvement of the Androgen and Glucocorticoid Receptors in Bladder Cancer.

Authors:  Lucien McBeth; Maria Grabnar; Steven Selman; Terry D Hinds
Journal:  Int J Endocrinol       Date:  2015-08-10       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.